Limits...
Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Katsambas A, Peris K, Vena G, Freidmann P, Wozel G, Daudén E, Licu D, Placchi M, De La Brassinne M - Arch Drug Inf (2009)

Bottom Line: Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks.By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis.Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life.

View Article: PubMed Central - PubMed

ABSTRACT
This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis. Quality of life improved throughout the trial, with a 50% median improvement in DLQI score after 12 weeks of treatment. Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life.

No MeSH data available.


Related in: MedlinePlus

Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population; (b) Week 20, continuous-treatment population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2805869&req=5

fig02: Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population; (b) Week 20, continuous-treatment population.

Mentions: A total of 1192 patients from the ITT population had DLQI data at baseline while 1044 patients had DLQI data at Week 12. DLQI scores ranged from 0 to 30 at baseline, with a median of 10 (IQR 5.0–16.0). Median DLQI scores improved steadily from baseline to Week 12 (Figure 2a). Among patients from the ITT population who had DLQI data at Week 12, the median improvement from baseline was 5 points (IQR 1.0–10.0).


Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Katsambas A, Peris K, Vena G, Freidmann P, Wozel G, Daudén E, Licu D, Placchi M, De La Brassinne M - Arch Drug Inf (2009)

Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population; (b) Week 20, continuous-treatment population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2805869&req=5

fig02: Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population; (b) Week 20, continuous-treatment population.
Mentions: A total of 1192 patients from the ITT population had DLQI data at baseline while 1044 patients had DLQI data at Week 12. DLQI scores ranged from 0 to 30 at baseline, with a median of 10 (IQR 5.0–16.0). Median DLQI scores improved steadily from baseline to Week 12 (Figure 2a). Among patients from the ITT population who had DLQI data at Week 12, the median improvement from baseline was 5 points (IQR 1.0–10.0).

Bottom Line: Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks.By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis.Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life.

View Article: PubMed Central - PubMed

ABSTRACT
This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis. Quality of life improved throughout the trial, with a 50% median improvement in DLQI score after 12 weeks of treatment. Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life.

No MeSH data available.


Related in: MedlinePlus